Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E. Rojas J, et al. AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843. AIDS. 2018. PMID: 29746294 Clinical Trial.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
Rojas J, Blanco JL, Marcos MA, Lonca M, Tricas A, Moreno L, Gonzalez-Cordon A, Torres B, Mallolas J, Garcia F, Gatell JM, Martinez E. Rojas J, et al. J Antimicrob Chemother. 2016 Jul;71(7):1975-81. doi: 10.1093/jac/dkw078. Epub 2016 Mar 28. J Antimicrob Chemother. 2016. PMID: 27021341 Free article.
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. Among authors: rojas j. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, Blanch J, Inciarte A, Tricas A, Rodriguez A, Martinez-Rebollar M, Laguno M, Mallolas J, Sanchez-Palomino S, Plana M, Blanco JL, Martinez E. de Lazzari E, et al. Among authors: rojas j. AIDS. 2019 Oct 1;33(12):1891-1896. doi: 10.1097/QAD.0000000000002311. AIDS. 2019. PMID: 31335805 Clinical Trial.
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators). Inciarte A, et al. Among authors: rojas j. AIDS. 2020 Oct 1;34(12):1775-1780. doi: 10.1097/QAD.0000000000002643. AIDS. 2020. PMID: 32773471 Free PMC article.
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Blanco JL, Rojas J, de Lazzari E, Inciarte A, Subirana M, Callau P, Martinez-Rebollar M, Laguno M, Mallolas J, de la Mora L, Torres B, Gonzalez-Cordón A, Martinez E. Blanco JL, et al. Among authors: rojas j. J Antimicrob Chemother. 2022 Jun 29;77(7):1974-1979. doi: 10.1093/jac/dkac137. J Antimicrob Chemother. 2022. PMID: 35512339
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group. Leal L, et al. Among authors: rojas j. J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994089 Clinical Trial.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. Leal L, et al. Among authors: rojas j. J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994091 Clinical Trial.
Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E. Peñafiel J, et al. Among authors: rojas j. J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053. J Antimicrob Chemother. 2017. PMID: 28333231
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, Clotet B, Gatell JM, de Lazzari E, Martinez E; DOLAM Study Team. Blanco JL, et al. Among authors: rojas j. J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971. doi: 10.1093/jac/dky093. J Antimicrob Chemother. 2018. PMID: 29608685 Clinical Trial.
1,435 results